FGFR2 and cholangiocarcinoma: On the basis of positive results obtained in the FIGHT-202 study [15], the U.S. FDA has recently approved the anti-FGFR2 antibody pemigatinib (Pemazyre) in CCA patients harboring FGFR2 gene fusions (9–14% of patients) previously treated with chemotherapy.